PMC5991483_01
Clinical course of the patient since admission in the nephrology unit (week 0). Therapy and changes in CD19+ circulating B cells (A), 24 h proteinuria levels and neurological signs (B) before and up to 24 months after the first rituximab administration.
nihms958851f1.jpg
PMC5991483_01_nihms958851f1.jpg
F1
Circulating CD19+ B cells were fully depleted since after the first 2 rituximab administrations and recovered to normal levels at 24 months after rituximab infusion (Figure 1). Complete renal remission (defined as a decrease in proteinuria to less than 0.5 g/day of protein and disappearance of hematuria) was obtained at 3 weeks after starting rituximab therapy and maintained throughout the 2-year follow-up period (Figure 1 and Table 1).